Parkinson's disease (PD) is the most common neurodegenerative movement disorder and is often considered an aging, largely sporadic condition. However, a nontrivial subset of patients have an earlier onset or a family history that increases the likelihood of a genetic etiology. The authors note that 5–14% of people with PD experience onset before age 50 (early-onset Parkinson's disease, EOPD) and about 20% report a positive family history. These groups are enriched for rare, disease-causing variants compared with typical late-onset sporadic cases.
Expanding variant discovery in underrepresented populations is important because many disease-associated variants have population-specific frequencies or may be missed by genotyping arrays and targeted panels that were designed based on non-Latin-American reference data. The Latin American Research consortium on the Genetics of Parkinson's Disease (LARGE-PD) set out to characterize the genomic landscape of EOPD and familial PD in Latin American patients using whole-genome sequencing.
The stated objective was to perform variant screening across a set of PD-related genes to identify pathogenic, likely pathogenic, and variants of uncertain significance in individuals from LARGE-PD who had early-onset disease and/or a family history and who lacked previously identified pathogenic PD variants on genotyping arrays.
The analysis used short-read whole-genome sequencing on a subset of 263 individuals recruited to LARGE-PD who met the inclusion criteria of EOPD and/or reported familial PD and who did not have known pathogenic PD variants in prior genotyping data. The manuscript reports sequencing of this well-defined subset but does not provide additional sequencing parameters or bioinformatics pipeline details in the abstract; those specifics are not reported in the provided source text.
The investigators screened seven genes directly implicated in PD as primary targets and an additional 21 genes associated with related parkinsonian disorders as secondary targets. The screening aimed to detect pathogenic or likely pathogenic variants and to catalogue variants of uncertain significance within these gene sets in the Latin American cohort. The source text does not list the individual gene names or variant interpretation criteria in the abstract.
Among the 263 sequenced individuals, the study observed a monogenic burden—defined as the presence of pathogenic or likely pathogenic variants in primary and secondary PD genes—in 4.7% of participants. An additional 5.5% of individuals carried pathogenic or likely pathogenic variants associated with Gaucher's disease, and 2.7% harbored known risk variants in GBA1. These results indicate that a measurable fraction of EOPD and familial PD cases in this Latin American sample carry variants with established disease association or risk implications.
The authors emphasize that whole-genome sequencing enabled identification of previously unreported or underrepresented variants in this population that might be missed by array-based genotyping or narrow targeted panels. The abstract does not provide a detailed breakdown of specific variants, gene-level counts, or variant-level pathogenicity classifications beyond the aggregated percentages noted above.
By expanding the reported spectrum of disease-associated variants among Latin American individuals with EOPD or familial PD, the study suggests that more comprehensive sequencing approaches may improve detection of clinically relevant variants in underrepresented populations. The detection of pathogenic variants for Gaucher's disease and risk variants in GBA1 highlights the intersection of lysosomal genetics and PD risk in this cohort.
These findings support consideration of broader sequencing strategies when evaluating EOPD or familial PD in Latin American patients, while recognizing that array-based and targeted approaches could miss population-specific or novel variants. The abstract does not make clinical management recommendations, and it does not report follow-up functional or segregation analyses for the identified variants.
The work received ethical approval from the Institutional Review Board of the Cleveland Clinic Foundation (IRB #19-340). The authors confirm that participant consent and relevant ethical guidelines were followed. Data supporting the study findings are available from the corresponding author (I.F.M.) upon reasonable request and are planned for release through the Global Parkinson's Genetics Program (GP2) in a future data release.
The study was supported by multiple funders including the National Institutes of Health, the Michael J. Fox Foundation, the Parkinson's Foundation, the Alzheimer's Disease Sequencing Project, VA Puget Sound Health Care System, the Chan Zuckerberg Initiative, the American Parkinson Disease Association, Fulbright Colombia, the Colombian Ministry of Science, the Brazilian National Council for Scientific and Technological Development, and Aligning Science Across Parkinson's. The authors declared no competing interests.
The abstract summarizes cohort selection, sequencing approach, and aggregated variant findings but does not list the specific genes screened by name, individual variant calls, or detailed analytic methods in the provided text. Those details may be present in the full manuscript or supplementary materials; they are not reported in the source abstract provided here.